Abstract

SAM and SH3 domain-containing 1 (SASH1), a scaffold protein, is regarded as a tumor suppressor. Recent studies have verified the decreased expression of SASH1 in many tumors. Our previous clinical investigation found that SASH1 was widely expressed in normal brain tissues but reduced or absent in glioma tissues. However, the functions of SASH1 in normal astrocytes and the reasons for the reductions in SASH1 levels in glioma tissues are unclear. In this study, we found that in astrocytes, SASH1 functions in cell adhesion. We observed that knockdown of SASH1 expression in cultured astrocytes significantly decreased cell adhesion and increased invasion. Conversely, overexpression of SASH1 in C6 cells markedly promoted cell adhesion and decreased cell invasion. In addition, we found that the expression level of one member of the integrin family, integrin β8, was significantly reduced in SASH1-downregulated astrocytes and elevated in SASH1-upregulated C6 cells. Furthermore, the results of methylation and ChIP assays showed that the methylation level of the SASH1 gene was markedly higher in C6 cells than in astrocytes and that HMGB1 could bind to the CpG islands of the SASH1 gene. HMGB1 overexpression in astrocytes significantly increased the methylation level of the SASH1 gene. This study reveals, for the first time, that HMGB1 contributes to the methylation of the SASH1 gene, and our findings suggest that methylation downregulates the expression of the SASH1 gene and later reduces integrin β8 expression, thereby reducing cell adhesion and promoting cell migration.

Highlights

  • The expression of SAM and SH3 domain-containing 1(SASH1) was first reported to be significantly decreased in breast cancer samples by Zeller in 20031

  • After the astrocytes were treated with SASH1 siRNA for 3 days, the SASH1 mRNA and protein levels decreased to 25.6% and 42.9%, respectively, of the levels in the control siRNA group (Fig. 1B)

  • The mechanism by which SASH1 plays a role in normal astrocytes and the processes that lead to the decrease or loss of SASH1 expression are not clear to date

Read more

Summary

Introduction

The expression of SAM and SH3 domain-containing 1. (SASH1) was first reported to be significantly decreased in breast cancer samples by Zeller in 20031. The SASH1 gene is widely expressed in normal human tissue. This gene regulates cell growth, proliferation, and apoptosis and is involved in the development of a variety of diseases. Current studies regard SASH1 as a tumor suppressor gene. SASH1 gene function is reduced or absent in most human tumor cells, such as lung cancer[2], gastric cancer[3], colon cancer[4,5], cervical cancer[6], ovarian carcinoma[7], and thyroid cancer cells[8].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call